Russia announced that Sputnik V vaccine is 83% effective against Delta variant of coronavirus

The Russian vaccine Sputnik V for COVID-19 is about 83% effective against the delta variant of the coronavirus, lower than previously thought, the health minister, Mikhail Murashko, said on Wednesday.

Authorities blame the increase in coronavirus cases in June and July on the more contagious delta variant and the population’s reluctance to get vaccinated even though vaccines are widely available.

The vaccine’s developers said in June that Sputnik V was about 90% effective against the delta variant.

“The latest results show that the effectiveness rate is 83%.” Said the news agency TASS, the seat of Murashko.

The vaccine Twitter account also assures that the study showed a 94.4% efficiency in avoiding hospitalizations.

Alexander Gintsburg, director of Instituto Gamalea who developed the vaccine, said Wednesday in an interview with the newspaper Izvestia that Sputnik V was safe and effective against all strains of the coronavirus.

Russia, which has a population of about 144 million, has approved four domestically produced vaccines. It has registered almost 6.5 million infections since the start of the pandemic.

The efficacy of the other vaccines against Delta

As the Delta variant advances in the world at high speed being the predominant one in some cases, real-time studies seek to determine how effective the available COVID-19 vaccines are against this strain.

Experts agree that, in general, all inoculants offer strong protection against serious illness and hospitalization for the new coronavirus.

On Sunday, two reports published in medRxiv on Sunday, not yet peer reviewed, they said that Pfizer and BioNTech’s mRNA vaccine may be less effective than Moderna’s against the Delta variant, although it maintains good protection against hospitalization.

In the study, conducted with more than 50,000 patients in the Mayo Clinic Health System, the researchers found that the effectiveness of Moderna’s vaccine against infection had dropped to 76% in July, when the Delta variant predominated, from 86% in early 2021.

During the same period, the effectiveness of the Pfizer / BioNTech vaccine had dropped from 76% to 42%the researchers said.

While both vaccines remain effective in preventing COVID hospitalization, a booster shot may soon be needed for anyone who received the Pfizer or Moderna vaccines earlier this year, said the doctor Venky Soundararajan, of the Massachusetts data analysis company, nference, who led the study.

Similar are the results obtained by AstraZeneca, an inoculant applied massively by Argentina against COVID-19. This vaccine consists of two doses applied to people over 18 years of age and its second application is indicated 28 to 84 days after the first. Its general efficiency is around 76% in clinical trials in the United States.

Front of Delta variant, one dose of the Oxford AstraZeneca vaccine is likely to provide protection against symptomatic Delta variant infection, with efficacy reported in studies of the 67% in Canada and 33% in Scotland and England. Regarding the risk of hospitalization, there was an efficacy reported in studies of 88% in Canada and 71% in England.

With the complete schematic, AstraZeneca Oxford is likely to provide protection against symptomatic Delta variant infection, with efficacy reported in studies of 61% in Scotland and 60% in England. Finally, with the two inoculations and in relation to the risk of hospitalization, the pharmaceutical company reported that it recorded 92% coverage in England.